Connect with us

Politics

House Rejects AOC Amendment To Make It Easier To Study Psychedelic Drugs

Published

on

The House of Representatives rejected an amendment on Thursday that would have removed an existing rider that scientists say inhibits research into the therapeutic potential of Schedule I controlled substances such as psilocybin, MDMA and marijuana.

The amendment, introduced by Rep. Alexandria Ocasio-Cortez (D-NY) last week, would have eliminated a section of a large-scale appropriations bill stipulating that no federal dollars can be spent on “any activity that promotes the legalization of any drug or other substance in Schedule I.”

The presiding officer ruled that the measure was approved in a voice vote after the debate early Thursday morning, but that was reversed during a later roll call vote of 91 to 331.

“Academics and scientists report that provisions like this create [stigma] and insurmountable logistical hurdles to researching schedule I drugs like psilocybin and MDMA which have shown promise in end of life therapy and treating PTSD,” a summary of the amendment states.

The House Rules Committee cleared the proposal for floor consideration before the full chamber on Monday. However, during the same meeting it blocked a separate amendment that would have barred the Department of Education from denying or limiting funds to universities that allow the use or possession of medical cannabis on campus in a legal state.

Ocasio-Cortez’s measure was cosponsored by Reps. Lou Correa (D-NY), Ro Khanna (D-CA) and Matt Gaetz (R-FL).

“I’m a strong believer in evidence-based policymaking,” Ocasio-Cortez said during the floor debate. “And wherever there is evidence of good, we have a moral obligation to pursue and explore the parameters of that good. Even if it means challenging our past assumptions or admitting past wrongs.”

Describing the current situation researchers face as a “catch-22,” she said that the problem with the current policy is that it is “so vague and broadly interrupted that it prevents scientists from researching, examining and exploring avenues of treatment that could alleviate an enormous amount of suffering from medical conditions.”

Correa also spoke in support.

“We need legitimate, reliable research by universities and other institutions into the health benefits of cannabis and other substances,” he said. “This amendment will allow credible research institutions to conduct research by removing layers of paperwork that serve as hurdles meant to block such research. As more Americans, including veterans, use cannabis and so-called ‘magic mushrooms’ to manage or treat their pain or other health conditions, it’s important that doctors have the necessary information on the possible benefits, or not, of these substances.”

Correa called the amendment “both timely and very necessary” in light of recent local moves to reform criminal policies dealing with psychedelics.

Voters in Denver approved a local measure to decriminalize the substance last month, and the Oakland City Council unanimously passed a similar measure last week that also applies to other psychedelics including ayahuasca, mescaline and ibogaine.

Both Correa and Ocasio-Cortez spoke about the suicide rate among military veterans and the potential of psychedelics to help them with conditions such as post-traumatic stress disorder.

“Thirty percent of all military veterans have considered suicide. If a substance shows promise in treating PTSD, we have an obligation to study it,” Ocasio-Cortez said. “One of the leading causes of death in America today is suicide. So if a Schedule I drug shows clinical promise in treating and in treatment resistant depression, perhaps it is not the drug we should say morally wrong, but perhaps it is the law, the schedule, the statute.”

But Rep. Andy Harris (R-MD) rose to oppose the amendment, saying that it wouldn’t actually help to foster research, a goal he said he shares.

“The bottom line is, this is not the place and this won’t do what the authors in support of the amendment say it’s going to do. The fact of the matter is that the DEA is the one that enforces the classification of Schedule I. This bill does nothing to do with the DEA,” he argued. “The problem lies in the fact that it is a Schedule I drug and the appropriate way to deal with this is through an authorizing committee.”

A longtime opponent of legalization, Harris suggested that cannabis “induces psychosis in young people,” adding that it is “a gateway drug.”

The amendment, he said, “sends a bad signal” and isn’t just about marijuana. “It’s about every Schedule I drug. And there are very dangerous schedule 1 drugs.”

Rep. Scott Perry (R-PA) also spoke against the proposal.

“Do we want the federal government telling our families and our children, take this, it’s good for you?” he asked. “Maybe it is. I sure don’t think it is. I certainly don’t want my kids taking it and I don’t want the government promoting it.”

Citing the growing political support for marijuana reform at a time when tobacco use rates are at historic lows, Perry said, “now we’re going to tell the rest of the country, ‘let’s all start smoking marijuana instead.”

“I don’t think this is what the government should be promoting,” he said.

But Ocasio-Cortez argued that her amendment has bipartisan appeal.

“My colleagues on the other side of the aisle often bemoan the role of government and promote ideas of choice. And here I am happy in that spirit to agree,” she said. “We should get government and political opinion out of scientific research when we have seen and shown promise in a way that can help people and their medical needs.”

“I understand that the politics of this bill may make it difficult for some to support right now,” she said. “But I propose this amendment and urge my colleagues to support it because politics isn’t always about winning today, but it is about fighting for what is right in the future and for future generations.”

If Ocasio-Cortez’s amendment had passed through the House, and deleted from that chamber’s bill the longstanding prohibition on advocating legalization that was first enacted in 1996, that wouldn’t have necessarily meant that the rider would have ultimately been removed from federal law. The Senate Appropriations Committee has not yet introduced its version of the funding legislation.

The last few weeks has seen a significant uptick in cannabis reform being pursued through the congressional appropriations process, with multiple committee reports urging the adoption on marijuana legislation. Committees have called for provisions on regulating CBD, implementing hemp policies, lifting barriers to cannabis research, preventing impaired driving, protecting veteran benefits and requesting that the federal government reconsider its employment policies as it relates to federal workers who use cannabis in compliance with state laws.

On Tuesday, the House Appropriations Committee approved a spending bill that includes a section providing protections for banks that service state-legal marijuana business and also remove a longstanding rider that has blocked Washington, D.C. from using its own local tax dollars to legalize and regulate cannabis sales.

Anti-Marijuana Lawmakers Shut Down By Congressional Committee

Update: This story has been updated to include information about the roll call vote on the amendment.

Photo courtesy of Rick Proctor.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.

Kyle Jaeger is Marijuana Moment's Sacramento-based senior editor. His work has also appeared in High Times, VICE and attn.

Politics

Virginia Has Sealed 64,000 Marijuana Distribution Charges Since Legalization Took Effect This Summer

Published

on

“These aren’t just numbers and there are families attached.”

By Ned Oliver, Virginia Mercury

Virginia has sealed records documenting more than 64,000 misdemeanor marijuana distribution charges since the state legalized the drug in July.

The figure came out Thursday during a meeting of the legislature’s Cannabis Oversight Commission.

Officials said the records were scrubbed from the state’s criminal record database, which is used by employers like school boards, state agencies and local governments to screen employees.

The state had already sealed 333,000 records detailing charges of simple possession last year after the state reduced the offense to a civil infraction on par with a traffic offense, said Shawn G. Talmadge, the Deputy Secretary of Public Safety and Homeland Security.

Lawmakers directed the state to expand that effort when they voted to broadly legalize recreational use of marijuana earlier this year.

The legislature also agreed to a broader expungement reform that will automatically seal other misdemeanor charges, including underage possession of alcohol, use of a fake ID, petit larceny, trespassing and disorderly conduct. Talmadge said those charges will remain in the system until the state finishes updating the software it uses to track criminal records.

“As of right now, the process is proceeding,” he said.

Members of the oversight commission also heard from two advocates who urged them to move fast to address people currently imprisoned for marijuana offenses—a category of people the legalization legislation passed this year did not address.

Chelsea Higgs Wise, the leader of the advocacy group Marijuana Justice, and Gracie Burger, with the Last Prisoner Project, said Department of Corrections data suggests there are currently 10 people being held solely on serious marijuana charges.

They said it remains unknown how many more are being held because of marijuana related probation violations.

“These aren’t just numbers and there are families attached,” Burger said.

This story was first published by Virginia Mercury,

Nevada Sold More Than $1 Billion In Marijuana In One Year, Officials Report

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Politics

DEA Proposes Dramatic Increase In Marijuana And Psychedelic Production In 2022, Calling For 6,300 Percent More MDMA Alone

Published

on

The Drug Enforcement Administration (DEA) is proposing a dramatic increase in the legal production of marijuana and psychedelics like psilocybin, LSD, MDMA and DMT to be used in research next year.

In a notice scheduled to be published in the Federal Register on Monday, the agency said there’s been a “significant increase in the use of schedule I hallucinogenic controlled substances for research and clinical trial purposes,” and it wants authorized manufacturers to meet that growing demand.

DEA had already massively upped its proposed 2021 quota for cannabis and psilocybin last month, but now it’s calling for significantly larger quantities of research-grade marijuana and a broader array of psychedelics to be manufactured in 2022.

It wants to double the amount of marijuana extracts, psilocybin and psilocyn, quadruple mescaline and quintuple DMT. What especially stands out in the notice is MDMA. The agency is proposing an enormous 6,300 percent boost in the production of that drug—from just 50 grams in 2021 to 3,200 grams in the coming year—as research into its therapeutic potential continues to expand.

LSD would see a 1,150 percent increase, up to 500 grams of the potent psychedelic.

Marijuana itself would get a 60 percent boost under DEA’s proposal, up to 3.2 million grams in 2022 from the 2 million grams last year.

Here’s a visualization of the proposed quota increase from 2021 to 2022 for marijuana and cannabis extracts:

For all other THC, psilocybin, psilocyn and MDMA:

And for other psychedelic substances like LSD, mescaline and DMT:

DEA said in the Federal Register notice that it has been receiving and approving additional applications to “grow, synthesize, extract, and manufacture dosage forms containing specific schedule I hallucinogenic substances for clinical trial purposes” to achieve these ambitious quotas.

“DEA supports regulated research with schedule I controlled substances, as evidenced by increases proposed for 2022 as compared with aggregate production quotas for these substances in 2021,” the agency said, adding that it working “diligently” to process and approve marijuana manufacturers applications in particular, as there’s currently only one farm at the University of Mississippi that’s permitted to cultivate the plant for research.

“Based on the increase in research and clinical trial applications, DEA has proposed increases in 3,4- Methylenedioxyamphetamine (MDA), 3,4-Methylenedioxymethamphetamine (MDMA), 5-Methoxy-N,N-dimethyltryptamine, Dimethyltryptamine, Lysergic acid diethylamide (LSD), Marihuana, Marihuana Extract, Mescaline, Psilocybin, Psilocyn, and All Other Tetrahydrocannabinols to support manufacturing activities related to the increased level of research and clinical trials with these schedule I controlled substances.”

Here are the exact numbers for the proposed 2021 and 2022 quotas:

Substance 2021
2022 proposed
Marijuana 2,000,000 3,200,000
Marijuana extract 500,000 1,000,000
All other tetrahydrocannabinol 1,000 2,000
Psilocybin 1,500 3,000
Psilocyn 1,000 2,000
MDMA 50 3,200
LSD 40 500
Mescaline 25 100
DMT 50 250
5-MeO-DMT 35 550
MDA 55 200

A 30-day public comment period will be open after the notice is formally published on Monday.

It’s difficult to overstate just how significant the proposed 2022 increases are, but it’s certainly true that scientific and public interest in marijuana and psychedelics has rapidly increased, with early clinical trials signaling that such substances show significant therapeutic potential.

National Institute on Drug Abuse (NIDA) Director Nora Volkow told Marijuana Moment in a recent interview that she was encouraged by DEA’s previous proposed increase in drug production quota. She also said that studies demonstrating the therapeutic benefits of psychedelics could be leading more people to experiment with substances like psilocybin.

Advocates and experts remain frustrated that these plants and fungi remain in the strictest federal drug category in the first place, especially considering the existing research that shows their medical value for certain conditions.

A federal appeals court in August dismissed a petition to require the DEA to reevaluate cannabis’s scheduling under the Controlled Substances Act. However, one judge did say in a concurring opinion that the agency may soon be forced to consider a policy change anyway based on a misinterpretation of the therapeutic value of marijuana.

Separately, the Washington State attorney general’s office and lawyers representing cancer patients recently urged a federal appeals panel to push for a DEA policy change to allow people in end-of-life care to access psilocybin under state and federal right-to-try laws.

Singer Melissa Etheridge And Activist Van Jones Promote Psychedelics Reform As Movement Grows

Image element courtesy of Kristie Gianopulos.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Politics

Supreme Court Won’t Hear Case On Legalizing Safe Drug Consumption Sites, But Activists Are Undeterred

Published

on

The U.S. Supreme Court (SCOTUS) has rejected a request to hear a case on the legality of establishing safe injection sites where people can use illicit drugs in a medically supervised environment.

The justices announced on Tuesday that they decided against taking up the case raised by the nonprofit Safehouse, despite the pleas of attorneys general from 10 states and D.C. who recently filed amici briefs urging the court’s involvement.

Representatives from 14 cities and counties, as well as the mayor of Philadelphia, which is at the center of the current case, also filed briefs in support of the case in recent days.

Safehouse was set to launch a safe consumption site in Philadelphia before being blocked by a legal challenge from the Trump administration. It filed a petition with the nation’s highest court in August to hear the case.

But while the Supreme Court declined to take action—and the Biden administration passed up its voluntary opportunity to weigh in at this stage, which may well have influenced the justices’ decision—activists say the battle will continue at a lower federal court level, where the administration will have to file briefs revealing its position on the issue.

“We were disappointed that the government chose not to respond to our petition,” Safehouse Vice President Ronda Goldfein told Filter. “They said, ‘We’re going to waive our right to respond,’ [and] the Supreme Court declined to review our case. Ordinarily that sounds like the end of the road—but in our case we are still pursuing our claims in a different venue.”

That venue will be the the federal district court in Philadelphia, where activists plan to submit multiple arguments related to religious freedom and interstate commerce protections. The Biden administration will be compelled to file a response in that court by November 5.

“If they don’t respond, they lose,” Goldfein said.

A coalition of 80 current and former prosecutors and law enforcement officials—including one who is President Joe Biden’s pick for U.S. attorney of Massachusetts—previously filed a brief urging the Supreme Court to take up Safehouse’s safe injection case.

Fair and Justice Prosecution, the group that coordinated the amicus brief, also organized a tour of Portugal for 20 top prosecutors in 2019 so they could learn about the successful implementation of the country’s drug decriminalization law.

If the Supreme Court were to have taken the case and rule in favor of Safehouse, it could have emboldened advocates and lawmakers across the country to pursue the harm reduction policy.

The governor of Rhode Island signed a bill in July to establish a safe consumption site pilot program where people could test and use currently illicit drugs in a medically supervised environment. It became the first state in the country to legalize the harm reduction centers. It’s not clear whether the Department of Justice will seek to intervene to prevent the opening of such facilities in that state.

Massachusetts lawmakers advanced similar legislation last year, but it was not ultimately enacted.

A similar harm reduction bill in California, sponsored by Sen. Scott Wiener (D), was approved in the state Senate in April, but further action has been delayed until 2022.

Florida Democratic Candidates For Governor Fight Over Who Supports Marijuana Reform The Most

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading
Advertisement

Marijuana News In Your Inbox

Support Marijuana Moment

Marijuana News In Your Inbox

Marijuana Moment